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Abstract 
In this contribution, we propose a system-level compartmental 
population dynamics model of tumour cells that interact with 
the patient (innate) immune system under the impact of 
radiation therapy (RT). The resulting in silico - model enables 
us to analyse the system-level impact of radiation on the 
tumour ecosystem. 
 The Tumour Control Probability (TCP) was calculated for 
varying conditions concerning therapy fractionation schemes, 
radio-sensitivity of tumour sub-clones, tumour population 
doubling time, repair speed and immunological elimination 
parameters. The simulations exhibit a therapeutic benefit when 
applying the initial 3 fractions in an interval of 2 days instead 
of daily delivered fractions. This effect disappears for fast-
growing tumours and in the case of incomplete repair. The 
results suggest some optimisation potential for combined 
hyperthermia-radiotherapy.  
 Regarding the sensitivity of the proposed model, cellular 
repair of radiation-induced damages is a key factor for tumour 
control. In contrast to this, the radio-sensitivity of immune cells 
does not influence the TCP as long as the radio-sensitivity is 
higher than those for tumour cells. The influence of the tumour 
sub-clone structure is small (if no competition is included). 
This work demonstrates the usefulness of in silico – modelling 
for identifying optimisation potentials. 
Introduction 
Cancer remains to be one of the most elusive widespread 
diseases – accounting for an estimated 16% of worldwide 
deaths.1 In the last decades, many improvements concerning 
equipment and treatment planning tools have driven anti-
cancer radiation therapy (RT) towards precise applications of 
radiation doses. Remarkable progress has been made regar-
ding geometrical precision. In contrast to these more enginee-
ring – related aspects, the biological knowledge about growth 
dynamics and therapy response of tumours seems to remain 
behind technology development. This may be a reason for the 
upcoming discussion of a biologically adapted RT (Thor-
warth, 2017). 
 One of the reasons for the comparably slow progress of 
biological understanding lies in the differences between the 
behaviour of tumour cells in vitro, in vivo (mouse model) and 
                                                             
1 https://ourworldindata.org/causes-of-death 
in patient, which, on the one hand, prevent a direct transfer of 
knowledge gained by experiments to clinical treatment, and on 
the other hand, indicate that cancer is a systemic disease that 
can only be understood by treating tumours as complex 
systems that are intricately coupled to their host environment 
including the immune system. 
Several studies consequently hypothesize that the major 
cause of radio-resistance observed during RT treatments may 
be related to the heterogeneity of tumour tissues (Horsman et 
al., 2012; Baumann et al., 2016). Under this systemic perspec-
tive, cancer might be regarded as an evolving ecosystem of 
diverse cell populations (different tumour sub-populations or 
sub-clones, host tissue, endothelial cells / vascular system, 
immune cells) with a dynamic behaviour influenced by the 
boundary conditions of RT. In such a framework, radiation-
induced cell killing would constitute a selection pressure that 
leads to survival of radio-resistant sub-populations. Loss of 
competition between the different cancer sub-populations and 
host tissue might lead to an accelerated progress of disease. 
Evolutionary dynamics of cancer (Crespi & Summers, 2005) 
could be responsible for an adapted response of the tumour to 
anti-cancer therapy.  
Ecological aspects of anti-cancer therapy have been discus-
sed by different authors (Pienta et al., 2008; Basanta et al. 
2015; Basanta et al., 2012). Merlo et al. (2006) considered 
cancer as an evolutionary and ecological process. Gatenby et 
al. pointed out the role of evolutionary dynamics for cancer 
prevention (Gatenby et al., 2010). Ecological principles have 
also motivated the investigation of the invasion of meta-
stasizing cancer cells into bone marrow (Chen & Pienta, 
2011). The connection between artificial life and cancer 
research has been pioneered by Maley and Forrest (2000) who 
developed an agent based model of precancerous cells that 
might develop into cancer by adopting mutations at atypically 
high rate. Population dynamics of tumours have been further 
studied by Gonzales-Garcia et al. (2002) and Sole (2003) who 
concluded through agent-based modelling that spatial genetic 
heterogeneity observed in tumours naturally follows from 
simple ecological competitor dynamics. Since then, many 
multi-agent models of tumour growth with increasing physical 
accuracy have been proposed (Abbott et al. 2006, Zhang et al. 
2009, Bentley 2013, Ozik et al. 2018 and others). Yet, few of 
these approaches take into account the dynamics of and 
interaction with the tumour environment, particularly host 
tissue, immune system, and boundary conditions imposed by 
anti-cancer therapies. 
Scheidegger et al. (2010) demonstrated by a combined 
population model in silico that - in certain situations - the 
tumour response to radiation is dominated by the radio-
sensitivity of the endothelial cells. In the light of these results, 
there is certain evidence that tissue dynamics could play a 
pivotal role in development and therapy response of tumours. 
Scott et al. (2016) investigated the impact of spatial metrics 
onto the radiation efficacy using a hybrid cellular automaton 
model.  
Despite this increased appreciation of ecological and evolu-
tionary aspects of cancer dynamics, relatively little work has 
been performed that attempts to transfer well-established met-
hodological approaches from theoretical ecosystem analysis to 
the domain of RT. 
We here propose a high-level population dynamics model 
of tumour cell populations that interact with a simplified im-
mune system under the impact of RT treatment (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structure with the different sub-models of a simpli-
fied tumour - immune system model. IC med. elimination 
means immune cell mediated cell killing. 
 
 
Due to the shear complexity of the biological tumour system 
and its response to both, the immune system and RT, we 
regard it as unpromising to bring the mechanistic details of the 
tumour ecosystem into a computer model: many of details are 
un-known and quantifiable experimental insight into most of 
the different dynamic processes is missing. Therefore, we 
propose a system dynamics-based phenomenological model, 
in order to support hypothesis generation and design of 
experiments in vitro or clinical trials. While our approach 
sacrifices many of the mechanistic details underlying tumour 
growth and treatment, the model has been developed with 
clinical applicability in mind: model parameters are in 
principle measurable and chosen to represent realistic 
parameter ranges, and model predictions are reported through 
clinically meaningful quantifiers. 
By improving the systemic understanding of tumour eco-
systems, quantitative in silico analysis of system-level cancer 
models could subsequently help to improve or optimize anti-
cancer treatment strategies. This broadened ecological and 
evolutionary view on the impact of RT onto tumours could be 
an important step for understanding the dynamics responsible 
for treatment response and may serve as a basis to optimize 
and improve RT treatments.  
In this work, we will focus on the optimisation potential 
regarding fractionation schemes in External Beam Radiation 
Therapy (EBRT). In case of an EBRT, the radiation is applied 
by fractions with a dose per fraction of e.g. 2 Gy for prostatic 
adenocarcinoma (Fowler et al., 1995). Typically, the standard 
fractionation scheme for EBRT for adeno-carcinomas is a 
daily application of the fractions (5 days per week). There is a 
recent discussion about hypo-fractionation (less fractions with 
a higher radiation dose) for example using daily fraction doses 
of 2.75 Gy (e.g. non-small lung cancer; De Dios et al. 2017). 
Arguments for choosing a fractionated application are related 
to the 4 R’s in RT: Repair (host tissue has faster repair 
compared to tumour cells, fractionation leads to a larger, so 
called “therapeutic window”), Repopulation (longer interval 
will allow tumours to repopulate), Re-oxygenation (reduction 
of tumour mass will enhance oxygenation and therefore 
increase radio-sensitivity of the tumour cells for subsequent 
fractions) and Redistribution (mitotic cells are more radio-
sensitive and radiation-induced cell killing can cause a 
synchronisation of tumour cells regarding the cell cycle). 
Fraction size and time interval between fractions should be 
optimised: long intervals lead to unwanted tumour growth and 
complete repair of tumour cells, short intervals to less re-
oxygenation and decreasing difference between cellular repair 
of tumour cells and host tissue (smaller therapeutic window). 
It has to be pointed out here that this is only a simplified 
explanation, not referring to the full ecosystem dynamics and 
excluding the aspect of immune system interaction. Exploring 
artificial life in silico could support modelling the immune 
system interaction and improve the understanding of the 
complex dynamics including pattern recognition.  
Materials and Methods 
The model describes tumour cell populations ( )k kT T t inter-
acting with an immune cell population ( )M M t . Both, im-
mune cells and tumour cells are considered to be radio-sen-
sitive. For modelling the radiation-induced elimination, a sim-
plified -LQ-model is applied (Scheidegger et al. 2011a). In 
this model, the elimination rate of tumour cell is determined 
by the radio-sensitivity constants  and  (which are consi-
dered to be population-specific) and the radiation dose rate R: 
 
  2k k k k k
Rad
dT R T
dt
            (1) 
 
and for the immune cells: 
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The dose equivalent  (Transient Biological Dose Equivalent 
TBDE, the unit is Gray (Gy)) is rising with the dose rate R 
and decaying with cellular repair: 
  , ,( )
k M
k M
d
R f
dt
    (3) 
 
In contrast to the full -LQ-model (Scheidegger et al. 2011a), 
dose rate dependence is not considered (fixed dose rate) and 
repair is switched off during irradiation. Integration of Eq.3 
leads to the well-established linear-quadratic model, where the 
logarithm of the surviving fraction S is given by a linear and a 
quadratic term of the radiation dose D: 2log ( )S D D    . 
For repair, first order kinetics is assumed: , , ,( )k M k M k Mf    . 
For the tumour cells (TBDE = k ), two cases are examined: 
Complete repair - is assumed when the remaining dose 
equivalent (TBDE) is smaller than 1 mGy – and incomplete 
repair (TBDE ≥ 1mGy). 
The growth of the tumour cell populations is determined 
by a growth constant Tk which is here chosen to be constant 
for all populations (sub-clones). Tumour cells can mutate with 
the rate mut kk T  to form or join another tumour sub-clone 1kT  . 
In addition to the radiation-induced elimination, tumour cells 
can be eliminated by the immune cells M. The development of 
the population size of the tumour cell population kT  is given 
by: 
 
 1 ,( )k kT k mut k k k ime k k
Rad
dT dTk T k T T w k T M
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          (4) 
 
 
kw is an immune-response specific weighting factor for the 
population k. Different weights can be explained by the fact 
that the immuno-biological sensitivity may be influenced by 
the mutation in two ways: (i) Higher sensitivity is gained by 
an increased genetic instability of tumour cells collecting 
more mutations and (ii) decreasing immuno-sensitivity can be 
achieved by an evolutionary process due to immune-system 
driven selection of tumour cells expressing less detectable an-
tigens on their surface (immunoediting by immune system 
(Vesely et al. 2011); escape from the immune response by 
reduction of self-antigen presenting Class I Major Histo-
compability Complex MHC). 
Tumour cells that have been eliminated from the 
population kT are transformed to apoptotic or necrotic cells 
kN . These cells - and with them, the amount of radiation 
induced Damage Associated Membrane Proteins DAMP’s 
(Grimsley et al., 2003) - can be eliminated by apoptosis and 
phagocytosis: 
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Rad
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In this model, no explicit pathway (apoptotic or necrotic, s. 
discussion) is chosen. In vivo, apoptotic cells are removed by 
macrophages, whereas necrosis may be accompanied by 
inflammation, leading to a more complex immune response. 
Natural killer cells can respond in absence of self-antigen 
presenting MHC and may be activated by DAMP’s. DAMP’s 
such as Heat Shock Proteins HSP (Srivastava, 2002, Daugaard 
et al., 2007) can be produced by ionizing radiation and are 
thus expressed in higher levels after RT (Nytko et al., 2019). 
The presented in silico model includes only one immune cell 
population. For simplicity, the activation of the (innate) 
immune system is assumed to be governed by the abundance 
of DAMP’s in the tumour compartment, leading to an 
invasion of immune cells until an equilibrium level (or 
response level) respM  is reached. Immune cells can be 
eliminated by radiation in the tumour compartment during RT. 
In consequence, the immune cell population in the tumour 
compartment is described by: 
 
 
  M resp
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The DAMP-activation of the response level respM  is assumed 
to be dependent on the sum of damaged cells by the following 
model: 
 
 min max 1
k
k
r N
respM M M e
       
 (7) 
 
 
minM and maxM are limiting the amplitude of the response to a 
range between a minimal concentration ( minM  per tumour 
compartment volume) of immune cells and a saturation level. 
Both levels may be dependent on patient specific immune 
response capability.  
 For clinical evaluation of the RT treatments, the Tumour 
Control Probability (TCP) is a well-established quantity. The 
TCP is calculated in the following way: 
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The concept behind Eq.8 is based on the fact that the 
description using differential equations delivers average popu-
lation sizes. For small amounts of cells, statistical variation 
has to be taken into consideration. 
In this study, EBRT was simulated by 32 fractions, each 
fraction with a radiation dose of 2.5 Gy. The fractionation 
schemes differ by the interval between the applications of RT 
fractions. A scheme with daily application was compared to 
fractionation with larger intervals of 2-4 days and a mixed 
scheme, where the initial 3 fractions have a spacing of 2 days, 
followed by daily application of subsequent fractions. 
The simulations were carried out by numerical integration 
using a 4th order Runge-Kutta algorithm. The time increment 
was set to 5 110 dt    . 
Results 
Parameters used for the different simulations are summarized 
in Tab.1. The resulting TCP’s are displayed in Fig. 2 and Fig. 
3. In general, the selection of the parameter values is made in 
regard to the resulting TCP: The parameter values are 
restricted to a range which results in a rising TCP (0.01 < TCP 
< 0.99) between a dose of 35 Gy and 80 Gy. This represents 
more or less the clinical observations for the selected radio-
biological parameters. 
 
 
 
 Parameter values 
 
Diagram No. 
 
Fig.2 Fig.3 
M  /Gy-1 0.5 0.5 
M  /Gy-2 0.2 0.2 
k  / Gy-1  varying 0.310 (k=1)
k  / Gy-2  varying 0.0625 (k=1) k / d-1 10 (for all k) varying 
Tk  / d
-1 23.46 10  
except. Fig. 2d 
23.46 10
mutk / d
-1 35 10 35 10  
riek / d
-1 810  810  
imek / d
-1 910 , varying 
for sub-clones 
varying 
Mk / d
-1   
minM  10
6 106 
maxM  10
9 varying 
r 10-3 10-3 
 
Table 1: Parameter values used for the simulations:  and  
for the tumour are in the upper range, especially when 
comparing to clinical studies but these values and the /-
ratios are strongly varying across different patients and 
tumours (van Leeuwen et al., 2018); kT is corresponding to an 
intrinsic tumour doubling time of 20 d (for clinical observed 
doubling times s. Mehrara et al., 2007). 
 
 
The sensitivity of the model regarding the radio-biological 
parameters of the immune cells have been investigated by 
simulations using different M and M values: For simu-
lations with the parameter set of Fig. 2, varying M values 
do not have a significant impact on the TCP (less than 1%), as 
long as M > 0.3 Gy-1. This is also the case for varying M-
values (set to 10 d-1; invading immune cells are considered as 
not pre-irradiated). 
In a first step, the influence of different tumour cell popu-
lations on the dynamics of the system is investigated. In Fig. 
2, different scenarios regarding the radio-sensitivity and im-
munological interactions of tumour sub-clones (5 different 
populations) are shown.  The simulation included a phase of 
tumour evolution during 300 days before start of RT. The 
initial population size was set to 109 cells, leading to approx. 
123 10 tumour cells at the beginning of the treatment. It was 
assumed that all populations have a doubling time of 20 days 
(accordingly Tk  = 
23.46 10  d-1).  
In Fig. 2a & 2b, the tumour sub-clones are considered to 
become more radio-sensitive with increasing mutations (due 
to higher genetic disorder). With every mutation, the value of 
 increases with an equidistant step: 20.3 2 10 ( 1)k k      . 
A similar relation was applied for the -values: 
30.06 5 10 ( 1)k k      . The values for k=1 represent the 
case of an adeno-carcinoma. From an immunological perspec-
tive, tumour sub-clones may develop in two different direc-
tions: Increasing mutations can lead to a better immunological 
elimination (due to the decreased expression of “don’t eat 
me”-signals such as CD47 or inappropriate expression of 
other membrane-bound signalling molecules). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Tumour Control Probability TCP for a treatment of a 
tumour consisting on different sub-clones and different frac-
tionation schemes (1 d = 1 day interval between fractions, 2 d 
= 2 days interval etc., mixed = 2 days interval between the 
initial 3 fractions, subsequent fractions in 1 day interval). (a) 
sub-clones with increasing weights wk; (b) sub-clones with 
decreasing wk; (c) single sub-clone scenario with average 
radio-sensitivity and (d) single sub-clone scenario with 
varying tumour doubling times. 
 
 
 
The case with an enhanced immunological elimination for 
increasing k (with ,ime k imek k k  ) is shown in Fig. 2a: 
Increased intervals between the fractions lead to a decreased 
tumour control (TCP-curves shifting to the right). The best 
tumour control can be achieved with the so called mixed 
protocol (first 3 fractions in an interval of 2 days, subsequent 
fractions daily). The explanation for this behaviour can be 
found by investigating the temporal development of the 
tumour cell population: After the first RT-fraction, a high 
amount of tumour cells are eliminated by radiation, leading to 
a high amount of apoptotic (or necrotic) cells. These cells are 
activating the immune response which in turn “co-eliminates” 
viable tumour cells. Depending on the selected invasion speed 
(governed by Mk ), the elimination rate is low shortly after the 
end of irradiation, increases to a maximum after approxi-
mately 1 day and then decreases again. This effect can only be 
observed during the early (first to third) fractions. For the 
subsequent fractions, the immune system - mediated response 
becomes smaller due to the reduced amount of eliminated 
tumour cells and the radiation-induced elimination of immune 
cells during each irradiation. Therefore, repopulation (which 
is counteracting the immunological elimination) drives the 
outcome towards lower TCP-values, especially for larger 
intervals. This explains the lower tumour control for 
fractionation schemes having large intervals throughout the 
therapy course. 
Decreasing immunological elimination (Fig. 2b) with 
incresing k ( 1,ime k imek k k ) leads to similar results as in Fig. 
2a. The effect of the mixed protocol is stronger compared to 
Fig. 2a and the difference between 1 day and 2 days interval is 
smaller, indicating the positive effect of immunological 
elimination during longer intervals at the beginning of the RT-
course. It has to be pointed out here, that this result is influ-
enced by the tumour evolution during the 300 days before 
therapy starts (initial conditions: T1(0) = 109, Tk>1(0) = 0). 
The comparison of the different cases (Fig. 2a & b) leads 
to the question how important the detailed modelling of 
different tumour sub-clones is. Fig. 2c shows a tumour where 
only one tumour population is taken into consideration. To 
achieve a comparable TCP, the radio-biological parameters 
are adapted to 1 0.310  Gy-1 and 1 0.0625  Gy-2. The 
resulting TCP curve does not remarkably differ from the case 
exhibited in Fig. 2b, indicating a relatively small influence of 
the number of tumour cell populations considered in the 
model. 
Since repopulation is counteracting the cell killing, simu-
lations using different tumour doubling times (20 days, 10 
days and 5 days) were carried out (Fig. 2d). The comparison 
of the mixed protocol with daily applied fractions reveals a 
disappearing therapeutic gain of the mixed protocol for fast 
repopulating tumours. This can be explained by the smaller 
decrease of the tumour cell population during the 2-day 
intervals compared to the case with slow repopulation. 
Especially during the second day of these intervals, faster 
repopulation compensates the immune-related elimination.  
In Fig. 3, the response of one single tumour cell popu-
lation onto the mixed protocol vs. daily fractions is shown for 
different conditions for repair and immunological elimination. 
The effect of incomplete repair leads to a strongly increased 
tumour control for both, mixed and daily fractionation. The 
difference between mixed and daily fractionation disappears at 
 = 2 d-1. The remaining dose equivalent  after one day 
interval is 0.4 Gy, representing moderate incomplete repair. 
With  = 1 d-1, the remaining dose equivalent   is 1.5 Gy. In 
this case, the mixed protocol exhibits a slightly lower TCP 
compared to the daily fractionation, indicating the strong 
influence of repair onto the outcome. 
For an increased immunological elimination (kime = 10-8) 
and incomplete repair (Fig. 3b), the mixed protocol reaches 
always higher TCP values, but the effect remains small. Fig. 
3c shows the outcome for an increased immune cell density 
(governed by Mmax). In this case, the effect of the mixed 
protocol becomes clearly larger for complete repair. For 
incomplete repair ( = 1 d-1), the difference between the two 
fractionation schemes remains small. Interestingly, this 
behaviour does not change when Mmax is increased to 1013 and 
kime is set to 10-8 (Fig. 3d). The explanation for this small 
difference is the fact that after the first fraction of the 
treatment, the total number of tumour cells is reduced by over 
a factor 500 one day after irradiation. Therefore, subsequent 
fractions will not produce large amounts of apoptotic cells, 
resulting in a smaller activation of the immune system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Tumour Control Probability TCP for a treatment of a 
tumour with varying repair speeds (k =  = 1 d-1 = complete 
vs. ( = 2…10 d-1 = incomplete repair) and varying immune-
mediated elimination. Only mixed vs. daily fractionation is 
displayed. (a) kime = 10-9 d-1, Mmax = 109; (b) kime = 10-8 d-1, 
Mmax = 109; (c) kime = 10-9 d-1, Mmax = 1011; (d) kime = 10-10 d-1, 
Mmax = 1013. 
 
 
Discussion and Conclusions 
The presented model contains a simplistic approach to the 
tumour-immune system interaction. Therefore, the question is: 
What can we learn from such an artificial system in silico? 
Certainly, the presented model cannot be used as a predictive 
model, due to lack of any validation. Validation would require 
a comparison of model output to clinically observed TCP’s 
and measuring immune cell densities during treatment.  
The model includes an innate immune system type response 
and does not differentiate between the diverse populations of 
immune cells and their specific role in developing immune 
reaction. The interference with the adaptive immune response 
via antigen-presenting cells may strongly modify the tumour-
specific response. 
For assessing the kinetic constants, tumour-immune system 
interactions should be tracked during treatment to acquire 
time-resolved data. This is associated with big challenges even 
for a clinical trial and is not realistic in clinical routine. A 
refinement of the immunological model would introduce a 
large number of additional parameters, many of them with 
large, patient-specific variations. To overcome these funda-
mental restrictions and difficulties, new approaches of model-
ling are needed. Looking to the immune system in its comp-
lexity, several network-structures involving signalling path-
ways and receptor signalling can be identified. Considering an 
adaptive immune system as a trainable network could lead to 
new insights to the dynamics of the tumour-immune-system 
interaction and – based on this - to new treatment concepts. 
However, there are some concerns for modellers and clini-
cians as well. The process of modelling itself and simulations 
often helps to refine ideas and concepts about the investigated 
system. Regardless of the uncertainty concerning the para-
meter values, the range of parameter values was restricted to 
achieve more or less clinically realistic tumour control. In this 
range, the presented model depicts some aspects of the funda-
mental dynamics regarding innate immune system activation 
in combination with radiation-induced cell killing. 
The model does not include competition between the 
tumour cell population and / or the host tissue, representing 
the situation of aggressive and fast growing tumours. In this 
regimen, considering different tumour sub-populations with 
varying radio-biological and immunological properties exhi-
bits only a small influence on the tumour control, at least for 
the investigated parameter range. Detailed modelling of sub-
clone – and host tissue interactions may become important 
when competition between the different populations reaches 
certain strength. 
 For description of the system, a compartmental model using 
ordinary differential equations is used. One may argue that 
some aspects of the ecosystem dynamics are related to the 
spatial distribution of cells / populations. Histological images 
from aggressive, highly malignant tumours often exhibit a 
more or less chaotic patchwork of host tissue, normoxic, hyp-
oxic and necrotic areas, proliferating and apoptotic tumour 
cells etc.. Considering highly malignant tumours, the added 
value of spatio-temporal models is unclear. Therefore, the 
influence of spatial aspects in function of tumour malignancy 
on tumour evolution is an interesting and important research 
topic.  
 The general system behaviour exhibits the strong influence 
of repair on tumour control for the selected  – and  – values 
(representing a tumour with comparably high radio sensiti-
vity). The reduced repair speed of tumour cells compared to 
the host tissue leads to a “therapeutic window” between TCP 
and Normal Tissue Complication Probability NTCP. No repair 
( = 0 d-1) will lead to survival which follows the linear-
quadratic law, independent of fractionation. This results in a 
non-realistic TCP. Depending on the repair speed, immune 
system mediated response seems to be circumstantial 
compared to the cell-intrinsic radiation biology (incomplete 
repair). But for the most of the investigated cases (over a wide 
range of parameter values), the mixed protocol exhibits a 
slight and for stronger immune response a clear advantage 
compared to the daily applied fractions. In clinical practice, 
daily application of RT fraction is normally limited to 
Monday-Friday with an interruption every week end. This 
results in a “mixed” fractionation scheme, where the 
appearance of the larger intervals during treatment course is 
defined by the starting day of the treatment. It has to be 
pointed out that there are many other fractionation schemes 
such as hypo-fractionation (e.g. de Dios et al., 2017), 
brachytherapy or stereotactic radio-surgery, which may 
support the idea of a biological treatment planning using in 
silico - models.  
There is some evidence for decreased tumour doubling time 
or increased rate of repopulation at the end of a treatment 
(Steel, 1977; Kim et al., 2005). This may be related to a 
smaller amount of tumour cells and related to this, less 
hypoxic cells or less competition. Another factor may be the 
selection of faster repopulating sub-clones during treatment 
course. The presented results are based on a constant tumour 
doubling. An accelerated growth at the end of RT treatment 
may be an additional argument for introducing longer inter-
vals at the start of the treatment course. 
For some indications, moderate hyperthermia is applied in 
combination with RT (HT-RT). In such therapy schemes, 
typically 3-6 RT-Fractions are combined with a hyperthermic 
treatment by heating the tumour tissue up to 42-43°C for 60-
90 minutes. The effect of moderate hyperthermia in combina-
tion with Radiotherapy (HT-RT) was demonstrated in clinical 
trials (e.g. Wust et al. 2002) and experimentally in vitro and in 
vivo. Several mechanisms which potentially contribute to the 
treatment response have been discussed (Streffer, 1995). The 
impact of heat in combination with radiation on the level of 
the tumour ecosystem has not yet been investigated. Beside 
many other effects, hyperthermia leads to an increased tissue 
perfusion. This may result in an improved accessibility of 
immune cells (and to a changed tumour micro-environment). 
In combination with the heat-induced expression of heat-
shock proteins (HSP), hyperthermia may enhance the intra-
tumour immune cell activity leading to additional cell killing. 
An indication for the importance of this process is the fact that 
HT-RT seems to have improved clinical outcome with only a 
small number of combined HT-RT fractions compared to the 
total number of applied RT-fractions. Regarding the results 
presented above, it could be an interesting option to combine 
heating and irradiation with longer intervals at the beginning 
of the HT-RT course. For avoiding thermotolerance induction, 
HT-RT treatments are applied with a spacing of 3-7 days. This 
has to be taken into consideration for optimising treatment 
schemes. Population-based models for combined HT-RT such 
as the Multi-Hit Repair (MHR) model (Scheid-egger et al. 
2013) can be integrated in the proposed frame-work to 
support therapy optimisation. 
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